EF Hutton Maintains Buy on Marinus Pharma, Maintains $23 Price Target
Portfolio Pulse from Benzinga Newsdesk
EF Hutton analyst Jason Kolbert has reiterated a Buy rating for Marinus Pharma (NASDAQ:MRNS) and maintained a price target of $23.
October 11, 2024 | 6:14 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
EF Hutton analyst Jason Kolbert has reiterated a Buy rating for Marinus Pharma and maintained a price target of $23, indicating confidence in the company's future performance.
The reaffirmation of a Buy rating and a maintained price target of $23 by EF Hutton suggests positive sentiment and confidence in Marinus Pharma's future performance. This is likely to have a positive short-term impact on the stock price as investors may view this as a strong endorsement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100